Treatment of climacteric symptoms in breast cancer patients: A retrospective study from a medication databank

Maturitas

Volumn 78, Issue 3, 2014, Pages 228-232

  Antoine, Caroline ^a   Ameye, Lieveke ^a   Paesmans, Marianne ^a   Rozenberg, Serge ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Breast cancer; Breast cancer survivors; Climacteric symptoms and treatment; Menopause

Indexed keywords

ANTIDEPRESSANT AGENT; AROMATASE INHIBITOR; CITALOPRAM; CLONIDINE; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; DIENOGEST PLUS ESTRADIOL VALERATE; DIVIPLUS; DIVIVA; DROSPIRENONE PLUS ESTRADIOL; DYDROGESTERONE; DYDROGESTERONE PLUS ESTRADIOL; ESTRACOMBI; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS NORGESTREL; ESTRIOL; ESTROFEM; ESTROGEN; FEMINOVA; FLUOXETINE; GABAPENTIN; GABAPENTINE; HERIA; LYNESTRENOL; NOGEST; NOMEGESTROL ACETATE; PAROXETINE; PREGABALIN; PROGESTERONE; TAMOXIFEN; TIBOLONE; TRISEQUENS; UNCLASSIFIED DRUG; VENLAFAXINE; 4 AMINOBUTYRIC ACID; AGENTS USED INTRAVAGINALLY; AMINE; ANTINEOPLASTIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ADULT; ARTICLE; CANCER PATIENT; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT INDICATION; AGED; BELGIUM; BREAST TUMOR; CLIMACTERIUM; COMPLICATION; DRUG INTERACTION; EARLY MENOPAUSE; ESTROGEN THERAPY; FACTUAL DATABASE; METABOLISM; MIDDLE AGED; SELF MEDICATION; SURVIVOR; UTILIZATION;

AGED; AMINES; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BELGIUM; BREAST NEOPLASMS; CLIMACTERIC; CLONIDINE; CYCLOHEXANECARBOXYLIC ACIDS; DATABASES, FACTUAL; DRUG INTERACTIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MENOPAUSE, PREMATURE; MIDDLE AGED; RETROSPECTIVE STUDIES; SELF MEDICATION; SURVIVORS; TAMOXIFEN; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84902649240     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2014.04.020     Document Type: Article

References (36)

1. J. Ferlay, F. Bray, P. Pisani, and D.M. Parkin GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1. 0IARC CancerBase No. 5 2001 IARC Press Lyon
2. American Cancer Society (ACS) Cancer Statistics Presentation 2004
3. D.A. Berry, K.A. Cronin, and S.K. Plevritis for the Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators Effect of screening and adjuvant therapy on mortality from breast cancer N Engl J Med 353 2005 1784 1792
4. P.J. Goodwin, M. Ennis, K.I. Pritchard, M. Trudeau, and N. Hood Risk of menopause during the first year after breast cancer diagnosis J Clin Oncol 17 1999 2365 2370
5. E.E. Lower, R. Blau, P. Gazder, and R. Tummala The risk of premature menopause induced by chemotherapy for early breast cancer J Womens Health Gend Based Med 8 1999 949 954
6. P.A. Ganz, J.H. Rowland, K. Desmond, B.E. Meyerowitz, and G.E. Wyatt Life after breast cancer: understanding women's health-related quality of life and sexual functioning J Clin Oncol 16 February (2) 1998 501 514
7. S.R. Davis, M. Panjari, P.J. Robinson, P. Fradkin, and R.J. Bell Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis Menopause March 2014 [Epub ahead of print]
8. P.F. Harris, P.L. Remington, A. Trentham-Dietz, C.I. Zllen, and P.A. Newcomb Prevalence and treatment of menopausal symptoms among breast cancer survivors J Pain Symptom Manage 23 2002 501 509
9. M.A. Cobleigh, R.F. Berris, and T. Bush et al. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group J Am Med Assoc 272 1994 540 545
10. N.F. Col, J.A. Kim, and R.T. Chlebowski Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence Breast Cancer Res 7 4 2005 R535 R540 [Epub 2005 May 19]
11. P. Batur, C.E. Blixen, H.C. Moore, H.L. Thacker, and M. Xu Menopausal hormone therapy (HT) in patients with breast cancer Maturitas 53 January (2) 2006 123 132
12. C. Antoine, F. Liebens, B. Carly, A. Pastijn, S. Neusy, and S. Rozenberg Safety of hormone therapy after breast cancer: a qualitative systematic review Hum Reprod 22 2 2007 616 622
13. L. Holmberg, and H. Anderson HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped Lancet 363 February (9407) 2004 453 455
14. P. Kenemans, M.W. Beckmann, and N.J. Bundred et al. Tibolone in breast cancer patients: first results of the LIBERATE Trial Climacteric May 11 Suppl. 2 2008 [meeting abstract SY-13-01, p. 25]
15. E. von Schoultz, L.E. Rutqvist, and Stockholm Breast Cancer Study Group Menopausal hormone therapy after breast cancer: the Stockholm randomized trial J Natl Cancer Inst 97 April (7) 2005 533 535
16. M. Fahlén, T. Fornander, and H. Johansson et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial Eur J Cancer 49 January (1) 2013 52 59
17. M. Hickey, C.M. Saunders, and B.G. Stuckey Management of menopausal symptoms in patients with breast cancer: an evidence-based approach Lancet Oncol 6 September (9) 2005 687 695
18. A. Gorins, M. Espié, and N. Bedairia et al. Hormonal replacement therapy in menopause after breast cancer: first French study Contracept Fertil Sex 26 October (10) 1998 696 699
19. M.B. Marttunen, P. Hietanen, S. Pyrhönen, A. Tiitinen, and O. Ylikorkala A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy Maturitas 39 September (3) 2001 217 225
20. R. Vassilopoulou-Sellin, D.S. Cohen, and G.N. Hortobagyi et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study Cancer 95 November (9) 2002 1817 1826
21. D.A. Decker, J.E. Pettinga, N. VanderVelde, R.R. Huang, L. Kestin, and J.H. Burdakin Estrogen replacement therapy in breast cancer survivors: a matched-controlled series Menopause 10 July-August (4) 2003 277 285
22. T. Kunovac Kallak, J. Baumgart, and A. Stavreus Evers et al. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients Climacteric 15 October (5) 2012 473 480
23. S. Pruthi, J.A. Simon, and A.P. Early Current overview of the management of urogenital atrophy in women with breast cancer Breast J 17 July-August (4) 2011 403 408
24. S. Wills, A. Ravipati, and P. Venuturumilli et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator J Oncol Pract 8 May (3) 2012 144 148
25. L. Mariani, A. Gadducci, E. Vizza, S. Tomao, and P. Vici Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy Gynecol Endocrinol 29 January (1) 2013 25 29
26. E.A. Lammerink, G.H. de Bock, C.P. Schröder, and M.J. Mourits The management of menopausal symptoms in breast cancer survivors: case-based approach Maturitas 73 November (3) 2012 265 268
27. A. Kendall, M. Dowsett, E. Folkerd, and I. Smith Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors Ann Oncol 17 April (4) 2006 584 587 [Epub 2006 January 27]
28. D.R. Pachman, J.M. Jones, and C.L. Loprinzi Management of menopause-associated vasomotor symptoms: current treatment options, challenges and future directions Int J Womens Health August (2) 2010 123 135
29. S. L'Espérance, S. Frenette, A. Dionne, J.Y. Dionne, and Comité de l'évolution des pratiques en oncologie (CEPO) Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations Support Care Cancer 21 May (5) 2013 1461 1474
30. C. Antoine, J. Vandromme, M. Fastrez, B. Carly, F. Liebens, and S. Rozenberg A survey among breast cancer survivors: treatment of the climacteric after breast cancer Climacteric 11 August (4) 2008 322 328
31. L. Holmberg, O.-E. Iversen, and C.M. Rudenstam et al. Increased risk of recurrence after Hormone Replacement Therapy in breast cancer survivors J Natl Cancer Inst 100 7 2008 475 482
32. C. Antoine, F. Liebens, B. Carly, A. Pastijn, and S. Rozenberg Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review Climacteric 10 February (1) 2007 23 26
33. V. Stearns, M.D. Johnson, and J.M. Rae et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 December (23) 2003 1758 1764
34. Y. Jin, Z. Desta, and V. Stearns et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 January (1) 2005 30 39
35. M. Dowsett, J. Cuzick, A. Howell, I. Jackson, and ATAC Trialists' Group Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial Br J Cancer 85 August (3) 2001 317 324
36. R.J. Couzi, K.J. Helzlsouer, and J.H. Fetting Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy J Clin Oncol 13 November (11) 1995 2737 2744